Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

AMYRIS INC (AMRS)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Amyris Inc : Lundin Law PC Announces a Securities Class Action Lawsuit against Amyris, Inc. and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2017 | 05:47am CEST

LOS ANGELES, CA / ACCESSWIRE / May 19, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Amyris, Inc. ("Amyris" or the "Company") (NASDAQ: AMRS) concerning possible violations of federal securities laws. Investors, who purchased shares between March 2, 2017 and April 17, 2017, inclusive (the "Class Period"), should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that during the Class Period, Amyris made false and/or misleading statements and/or failed to disclose: that in the first quarter of 2017, the Company made a decision to take an equity stake in one of Blue California's affiliates that focused on the sweetener market instead of cash payment under the license agreement; that due to this decision, Amyris would be unable to recognize $10 million in fourth quarter and fiscal year 2016 revenue from the license agreement with Blue California; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. Following this news, Amyris' stock price fell materially, which caused investors harm according to the Complaint.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles devoted to upholding shareholders' rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/

SOURCE: Lundin Law PC


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYRIS INC
04/18AMYRIS, INC. : Regulation FD Disclosure (form 8-K)
AQ
04/17AMYRIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
04/12AMYRIS, INC. (NASDAQ : AMRS) Files An 8-K Entry into a Material Definitive Agree..
AQ
04/12AMYRIS, INC. : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
04/11AMYRIS : Biossance – Introducing 3 New Ways to Sample
PU
04/06AMYRIS, INC. (NASDAQ : AMRS) Files An 8-K Entry into a Material Definitive Agree..
AQ
04/06AMYRIS : to Present at H.C. Wainwright Global Life Sciences Investment Conferenc..
AQ
04/05AMYRIS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/04AMYRIS : to Present at H.C. Wainwright Global Life Sciences Investment Conferenc..
AQ
04/03Amyris to Present at H.C. Wainwright Global Life Sciences Investment Conferen..
GL
More news
News from SeekingAlpha
2017Amyris (AMRS) Investor Presentation - Slideshow 
2017Amyris' (AMRS) CEO John Melo on Q1 2017 Results - Earnings Call Transcript 
2017Amyris misses by $0.04, misses on revenue 
2017Notable earnings after Monday?s close 
2017INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Apollo Global, Pulse Biosciences, Acacia .. 
Financials ($)
Sales 2018 189 M
EBIT 2018 -6,33 M
Net income 2018 -28,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 31,10
Capi. / Sales 2018 1,45x
Capi. / Sales 2019 0,98x
Capitalization 273 M
Chart AMYRIS INC
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 12,5 $
Spread / Average Target 91%
EPS Revisions
Managers
NameTitle
John G. Melo President, Chief Executive Officer & Director
Geoffrey M. Duyk Chairman
Eduardo Alvarez Chief Operating Officer
Kathleen Valiasek Chief Financial Officer
Joel Cherry President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-67.12%273
HENKEL-7.30%53 269
ECOLAB9.00%42 834
SIKA-4.52%16 198
SYMRISE-6.09%10 639
INDORAMA VENTURES PCL--.--%10 231